

Consumer Health

Jully 2011



List of Contents and Tables

Tuon da	
Switches	
Competitive Landsca	pe
Prospects	
Table 1	Sales of Digestive Remedies by Category: Value 2005-2010
Table 2	Sales of Digestive Remedies by Category: % Value Growth 2005-2010
Table 3	Digestive Remedies Company Shares by Value 2006-2010
Table 4	Digestive Remedies Brand Shares by Value 2007-2010
Table 5	Forecast Sales of Digestive Remedies by Category: Value 2010-2015
Table 6	Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015
	2013
IVE REMEDIES IN	SWEDEN - COMPANY PROFILES
_	Consumer Health (sweden)
Summary 1	Abigo Medical AB: Key Facts
Summary 2	Abigo Medical AB: Operational Indicators
	g
	Abigo Medical AB: Competitive Position 2010
Competitive Positionin, Summary 3	
Competitive Positionin, Summary 3 Antula Healthcare At	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction	Abigo Medical AB: Competitive Position 2010 in Consumer Health (sweden)
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction	Abigo Medical AB: Competitive Position 2010 in Consumer Health (sweden)
Competitive Positioning Summary 3 Antula Healthcare At Strategic Direction Key Facts Summary 4	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts Summary 4 Summary 5	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Ale Strategic Direction Key Facts Summary 4 Summary 5 Company Background.	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare At Strategic Direction Key Facts Summary 4 Summary 5 Company Background. Production	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare At Strategic Direction Key Facts Summary 4 Summary 5 Company Background. Production	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts Summary 4 Summary 5 Company Background. Production	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts Summary 4 Summary 5 Company Background. Production Competitive Positioning Summary 6 Meda Ab in Consume	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts	Abigo Medical AB: Competitive Position 2010
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts	Abigo Medical AB: Competitive Position 2010 In Consumer Health (sweden) Antula Healthcare AB: Key Facts Antula Healthcare AB: Operational Indicators G Antula Healthcare AB: Competitive Position 2010 Thealth (sweden) Meda AB: Key Facts Meda AB: Operational Indicators
Competitive Positioning Summary 3 Antula Healthcare Alt Strategic Direction Key Facts	Abigo Medical AB: Competitive Position 2010



Executive Summary	
Resilience To Wider E	Economic Forces
Liberalisation Boosts	Sales Growth
Increasing Concentra	ted Environment
Distribution Increasin	igly Diverse
Positive Outlook	
Key Trends and Dev	elopments
	nues To Age
	Proves Resilient To Wider Economic Forces
Health and Wellness -	- A Driver of Sales
Swedish Consumers A	re More Willing To Self-medicate
Liberalisation Does N	lot Lead To Increased Price Competition
Market Indicators	
Table 7	Consumer Expenditure on Health Goods and Medical Services 2005-2010
Table 8	Life Expectancy at Birth 2005-2010
Table 9	Sales of Consumer Health by Category: Value 2005-2010
Table 10	Sales of Consumer Health by Category: % Value Growth 2005-2010
Table 11	Consumer Health Company Shares by Value 2006-2010
Table 12	Consumer Health Brand Shares by Value 2007-2010
Table 13	Penetration of Private Label by Category 2005-2010
Table 14	Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
Table 15	Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
Table 16	Forecast Sales of Consumer Health by Category: Value 2010-2015
Table 17	Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015
Appendix	
	l Classification
	ing Requirements
	Supplements Registration and Classification
Advertising	
Self-medication/self-c	are and Preventative Medicine
Switches	
	OTC Healthcare Switches 2008-2010



DIGESTIVE REMEDIES IN SWEDEN - CATEGORY ANALYSIS

HEADLINES

- Current value sales reach SEK641 million in 2010; an increase of 5%
- De-regulation and the continued ageing of the Swedish population are key growth drivers
- H2 blockers records the fastest retail value growth in 2010 at 7%
- McNeil Sweden AB is the leading category player with current value share of 19%
- Digestive remedies in Sweden is expected to reach constant value sales of SEK758 million by 2015, which represents an overall increase of 18%

TRENDS

- The ageing population is a key driver of category sales. Ageing can lead to difficulties in digesting food.
 Acidity, heartburn and constipation continue to offer good opportunities for growth of digestive remedies in
 Sweden. According to research undertaken by Novartis, approximately 36% of the Swedish population
 suffered from indigestion complaints in a given six month period. This statistic reveals the strong demand
 and growth potential for Swedish digestive remedies.
- In current retail value terms, growth in 2010 was slower than the 9% CAGR recorded for the review period.
 De-regulation, while strongly boosting the sales of certain segments such as H2 blockers and laxatives, did not have the same level of impact on total digestive remedies. This is because certain digestive remedies' availability, such as diarrhoeal remedies, continued to be controlled by chemists/pharmacies due to the possibility of consumer misuse.
- H2 blockers recorded the fastest retail value growth in 2010 at 7%. Sales of H2 blockers in 2010 benefitted from de-regulation, which led to an increase in product availability and distribution as grocery retailers are now permitted to carry and sell certain digestive remedies previously restricted to chemists/pharmacies. H2 blocker brands such as Pepcid Duo and Inside are now widely available via the grocery retailer channel.
- Despite the de-regulation of pharmacy sales, this did not have any real or significant influence on pricing developments in 2010. For example, the H2 Blockers brand Pepcid Duo was priced at SEK84.5 (12 unit packaging) by parapharmacies chain Apoteket in 2009. Subsequent de-regulation led to the brand being distributed via supermarkets. However, both Apoteket and the grocery retailer chain ICA Supermarket priced Pepcid Duo at SEK84.5 (12 unit packaging) in 2010.
- There are no child-specific digestive products in Sweden. This is because the overriding majority of
 products offer dosage recommendations for both adults and children. The existence of these dosage
 recommendations are stifling the development of child-specific sales as there is no clear and defining
 reason for consumers to purchase these products.
- Herbal/traditional digestive remedies accounted for just 2% share of overall sales in the category in 2010.
 These products are mainly present in digestive enzymes, but herbal/traditional products are also present in laxatives and diarrhoeal remedies. There are no strong herbal/traditional brands in these segments.
 Herbal/traditional products continued to lose share in 2010 compared with the previous year, as many consumers shifted back from herbal to standard products. This was a result of general opinion that standard products are more efficient than herbal products.
- The dietary discussion in Sweden is quite confused, and at the end of the review period, the focus was on high carbohydrate versus low carbohydrate diets, although a number of other diets and programmes are flourishing. Fast food has a poor reputation, but is working hard to improve its image, and menus were certainly healthier in 20010 than they were in 2005. This includes fast food chains such as McDonald's and domestic chain Max. Another trend is "back-to-basics", towards organic float with a such as McDonald is unconstitution.

تلفن: ۸۸۳٤٩۱۱۲ تماس حاصل فرمایید.



- preservatives or E-numbers. Indigestion problems are generally seen as a lifestyle problem, and certainly impact sales of indigestion and heartburn remedies.
- There are several influences in play when consumers choose digestive remedies. Price usually has marginal
 importance, as most products are affordable by the majority of households. Previous positive experience of
 a specific brand is one important influencing factor, as well as recommendations from friends, pharmacists
 and doctors.
- An ageing population, meals high in fats and irritants, and a rising urban population suffering from high stress all contribute to the continued adoption of irritable bowel syndrome (IBS) treatments. Indulgence periods such as Christmas, New Year and Easter lead to a seasonal peak in the consumption of digestive remedies.
- IBS treatments does not have OTC status in Swedish consumer health.

SWITCHES

• Eight digestive remedies were switched to OTC status in 2009: diarrhoeal remedy Imodium 2mg from McNeil Sweden AB, laxative Dulcolax 5mg and 10mg from Boehringer Ingelheim AB, laxative Pursennid 12mg from Novartis Sverige AB, laxative Laxido from Nordic Drugs AB and three proton pump inhibitors from Altana AG (owned by Nycomed AB), Pantoloc 20mg, Somac 20mg and Pantecta 20mg. Larger packaging sizes of Dulcolax and Pursennid were later (June 2009) switched back to Rx status after several reports of misuse by teenage girls (to aid weight loss).

COMPETITIVE LANDSCAPE

 In national brand owner terms, McNeil Sweden AB was the leading category player with a retail value share of 19% in 2010. McNeil Sweden is the NBO of several popular and leading digestive remedies brands in Sweden, including diarrhoeal remedy Imodium, H2 blocker Pepcid Duo and laxative Microlax.





PROSPECTS

- De-regulation will continue to drive sales growth over the forecast period. Similar to the review period, the continued ageing of the population will increase the absolute demand for digestive remedies.
- •
- •
- •
- •
- •
- •

CATEGORY DATA

Table 1	Sales of Digesti	ive Remedies by Categ	ory: Value 200	5-2010		
SEK million	4	2005 2006	2007	2008	2009	2010
Child-Specific Digestive Rer Diarrhoeal Rem IBS Treatments Indigestion and Heartburn Re Laxatives Motion Sickness Digestive Reme	edies medies Remedies					

Source: Euromonitor International from official statistics, trade associations, trade press, company research, store checks, trade interviews, trade sources

Table 2	Sales of Digestive Remedies by Category: % Value Growth 2005-2010
---------	---

% current value growth

2009/10 2005-10 CAGR 2005/10 TOTAL

Child-Specific Digestive Remedies Diarrhoeal Remedies



IBS Treatments

Indigestion and Heartburn Remedies

Laxatives

Motion Sickness Remedies

Digestive Remedies

Source: Euromonitor International from official statistics, trade associations, trade press, company research, store

checks, trade interviews, trade sources

Table 3 Digestive Remedies Company Shares by Value 2006-2010

% retail value rsp

Company 2006 2007 2008

Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 Source: Euromonitor International from official statistics, trade associations, trade press, company research, store

checks, trade interviews, trade sources

Table 4 Digestive Remedies Brand Shares by Value 2007-2010

% retail value rsp

Brand Company 2007 2008 2009 2010

برای دریافت اطلاعات بیشتر با شماره تلفن: ۸۸۳٤۹۱۱۲ تماس حاصل فرمایید.

2009

2010



Total 100.0 100.0 100.0 100.0

Source: Euromonitor International from official statistics, trade associations, trade press, company research, store checks, trade interviews, trade sources

Table 5 Forecast Sales of Digestive Remedies by Category: Value 2010-2015

SEK million 2010 2011 2012 2013 2014 2015

Child-Specific
Digestive Remedies
Diarrhoeal Remedies
IBS Treatments
Indigestion and
Heartburn Remedies
Laxatives
Motion Sickness Remedie

Motion Sickness Remedies

Digestive Remedies

Source: Euromonitor International from trade associations, trade press, company research, trade interviews, trade

sources

Table 6 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

% constant value growth

2010-15 CAGR 2010/15 TOTAL

Child-Specific Digestive Remedies Diarrhoeal Remedies IBS Treatments Indigestion and Heartburn Remedies Laxatives Motion Sickness Remedies

نمونه گزارش تحلیل بازار بهداشت فر<mark>دی در ایران</mark>



Digestive Remedies

Source: Euromonitor International from trade associations, trade press, company research, trade interviews, trade



DIGESTIVE REMEDIES IN SWEDEN - COMPANY PROFILES

ABIGO MEDICAL AB IN CONSUMER HEALTH (SWEDEN)

Strategic Direction

The company will seek consumer health sales growth through new product developments, specifically product groups that have newly received OTC status,

Key Facts

Summary 1 Abigo Medical AB: Key Facts

Full name of	of company:	Abigo Medical AS
Address:		EkElnomivagen 5, 436 33 Askim, Sweden
Tel		+46 (31) 748950
Fax:		+46 (31) 683951
www:		www.abigo.se
Activities:		Pharmaceuticals
Source:	Ratsit.se,companyresearch	

Summary 2 Abigo Medical AB: Operational Indicators

	2008	2009	2010(e)
Net sales (SEK million)	50.09	59.06	65
Net profit (SEK million)	128	2.5	3
Number of employees	29	30	31
Source: Ratsit se			

Company Background

- Abigo Medical is a small privately-owned Swedish pharmaceutical company operating mainly in Sweden, but also with international activities, The company is part of the family-owned Abigo Group, comprising Abigo Medical AB, DHC, Abigo A/S and Sylak AB,
- Abigo Medical offers its own licensed pharmaceutical and wound care products. It has approximately 35 on offer, both within Rx and OTC healthcare. Of these, the majority of the company's products have very small shares in their respective product categories,
- Company representatives claim that its future success will be due to its highly skilled personnel. The company's key personnel have on average 20 years experience in Swedish pharmaceuticals. Doctors, researchers and other people at universities and institutions together form an integral part of the company's expanding research and development network,

Production

Abigo' s production facilities are situated in Askim near Gothenburg and Askersund in Central Sweden. All of the company's products are produced in Sweden.

برای دریافت اطلاعات بیشتر با شماره
تلفن : ۸۸۳٤۹۱۱۲ تماس حاصل فرمایید.



~ Abigo exports its products to about 30 countries around the world.

Competitive Positioning

- The company's overall share in 20 10 was marginal, ranking Abigo 25th overall in Swedish consumer health.
- ~ The company's share declined in the latter years of the review period.

Abigos OTC healthcare operations comprise products across many areas. The company notably claims to have the most extensive line of vitamins on offer in Sweden, although its share of value sales was low in 2010 at just 2%.

Within consumer health, the company focuses mainly on niche product categories, in which it supplies low cost alternatives for Apoteket pharmacies.

The company rarely advertises its products, largely due to the small size of sales in the product areas in which it operates.

~ Abigos product portfolio has a standard to economy price positioning.

Summary3 Abigo MedicalAS: CompetitivePosition2010

Product type	Value share	.Rank
Consumer healthcare	0.6%	25
Calming and sleeping products	11.3%	4
Digestive remedies	05%	26
Laxatives	2.3%	9
Vitamins and dietary supplements	1.9%	10
Child-specific vitamins and dietary supplements	5.2%	6
Calcium supplements	5.0%	5
Multivitamins	3.8%	7
Single vitamins	1UI%	4

Source. EuromonitorInternationalfrom companyreports, companyresearch, trade sources, trade interviews

ANTULA HEALTHCARE AB IN CONSUMER HEALTH (SWEDEN)

Strategic Direction

Key Facts

Summary4	Antula HealthcareAS: KeyFacts		
Full name of co	om.pany:	Antula Healthcare	e AS
Address:		Dstermalmsgatan	19, 11426 Stockholm, Sweden
Tel:		+46 (8) 316 800	
Fax:		nfa	
www:		Antula.se	رافت اطلاعات بشتر را شماره



Activities: Sale, marketing and distribution of pharmaceuticals Source: EuromonitorInternationalfrom companyreports, companyresearch Summary5 Antula HealthcareAS: OperationalIndicators 2008 2009 2010 Removed Removed Removed Netsales (SEK million) Removed Removed Removed Net profit (SEK million) Removed --:R;:'emoved Number of employees Removed Source. Companyresearch, trade sources, retsit.se Company Background Antnia Healthcareis apharmaceutical companyfocusing on products approved to be sold without prescription (OTC) today or likely to be approvedOTC statusin the future. **Production** Competitive Positioning Summary6 Antula HealthcareAS: CompetitivePosition 2010 Producttype Value share .Rank Removed Removed Consumerhealthcare Removed Removed Adult mouth care Removed Removed Analgesics Removed Removed Diclofenac براى دريافت اطلاعات بيشته المناهجها ما ما Removed Naproxen تلفنْ : ۸۸۳٤٩۱۱۲ تماس حاصل فرمایید.



Digestiveremedies	Removed	Removed
H2 blockers	Removed	Removed
Motionsicknessremedies	Removed	Removed
Medicatedskin care	Removed	Removed
Hair losstreatments	Removed	Removed
Child-specificmedicatedskin care	Removed	Removed
Cold sore treatments	Removed	Removed
Haemorrhoidtreatments	Removed	Removed
OTCTriptans	Removed	Removed
Topical analgesics/anaesthetic	Removed	Removed

Source. Euromomtor International from company reports, company research, trade sources, trade interviews

MEDA AB IN CONSUMER HEALTH (SWEDEN)

Strategic Direction

Key Facts

Summary 7 Meda AS: Key Facts Full name of company: MedaAB Address: Box 906, SE-170 09 Solna, Sweden Tel: +468-6301900 +468-6301950 Fax: Meda.se www: Manufacture, sale and distribution of pharmaceuticals. Activities: Source. Euromomtor tniemetions: from company reports Summary 8 Meda AS: Operational Indicators 2008 Year end 31st Dec 2009 2010 Removed-Removed Net sales (SEK million) Removed Removed Removed Net profit (SEK million) Removed Number of employees Removed Removed Removed

Company Background

Source.

Euromonitor tniemetions: from company reports

MedaAB hasin the last decadeevolved into a leading international speciality pharmaceutical company
with full representation Europeand North America through its own salesorganisations 50 countries.



~		
~		
~		
~		N O
Production		
~		
~		
Summary 9 Meda AS: Production	n Statistics 2010	
Location	Brand	Annual production
Merignac, France	Removed	Removed
Cologne, Germany	Removed	Removed
Decatur, Illinois, US	Removed	Removed
Source. Euromonitor Internetione! fro	m company reports, company research	
Competitive Positioning		
~		
~		
~	7	
~		
~		
Summary 10 Meda AS: Competitive	ve Position 2010	
Product type	Value share	Rank
Consumer health	Removed	Removed
Digestive remedies	Removed	Removed
Indigestion and heartbum remedies	Removed	Removed
Antacids	Removed	Removed
Analgesics	Removed	Removed
Aspirin		برای دریافت اطلاعات بیشترههای همهاهه تلفن: ۸۸۳۶۹۱۱۲ ماسد حاصل فرمایید



Vitamins and dietary supplements Removed Removed

Source: Euromonitor International from company reports, company research, trade interviews



CONSUMER HEALTH IN SWEDEN - INDUSTRY OVERVIEW

EXECUTIVE SUMMARY

Resilience To Wider Economic Forces

Despite the weak economic climate, Swedish consumer health sales proved to be relatively immune to wider economic forces. Consumer health posted strong retail value growth once again in 2010, albeit slower than the CAGR recorded for the review period as a whole. Most mature consumer health categories proved to be resilient and posted healthy growth rates as consumers still needed to attend to their minor ailments. Growth in 2010 was also supplemented and supported by a number of other factors such as the self-medication trend, liberalisation of pharmacy sales, the continued ageing of the Swedish population and increased category segmentation.

Liberalisation Boosts Sales Growth

The de-regulation of pharmacy sales occurred in November 2009, leading to the entry of numerous new pharmacy chains. As part of this process the sale of certain OTC medicines was liberalised with distribution via mass market channels such as supermarkets and hypermarkets now possible. This change led to a strong boost in sales prompted by the greater availability and distribution of consumer health products. However, despite the de-regulation of pharmacy sales, subsequent entry of new players in pharmacy retailing sales and product availability in mass market channels, increased or significant price competition had yet to occur in Swedish consumer health at the end of the review period. The lack of price competition in the context of greater product distribution consequently encouraged the recording of strong current retail value growth rates for 2010.

Increasing Concentrated Environment

Consumer health's sales were increasingly characterised by consolidation; numerous categories are dominated by a handful of players. Indeed major players are not just confined to one area of consumer health but have an overall presence across the spectrum of total consumer health sales. 2010 was also a year that witnessed merger and acquisition activity. The domestic player, Meda AB, firmly stated strategic goals to establish itself as a leading player. This will be achieved through a combination of organic growth and acquisition, as the company's acquisition of BioPhausia OTC medicine product portfolio in September 2010 indicates.

Distribution Increasingly Diverse

Positive Outlook

KEY TRENDS AND DEVELOPMENTS



the Population Continues To Age **Current Impact** Outlook **Future Impact Consumer Healthcare Proves Resilient To Wider Economic Forces**



Current Impact	W 0'
Outlook	
Future Impact	
Tuture impact	

Health and Wellness - A Driver of Sales



Current Impact	
Outlook	
	467
Future Impact	
4 6	

Swedish Consumers Are More Willing To Self-medicate



Current Impact	W o
Outlook	
	A-37
Future Impact	
$\Delta \circ \gamma$	

Liberalisation Does Not Lead To Increased Price Competition



Current Impact	
Outlook	
Future Impact	

MARKET INDICATORS

Table 1	Consumer Exp	er Expenditure on Health Goods and Medical Services 2005-2010					
SEK million		2005	2006	2007	2008	2009	2010
Pharmaceutical	S.	2000	2000	2001			۲۰۱۰ برای دریافت
	-,						تلفن: ٤٩١١٢



medical appliances/ equipment Outpatient services Hospital services Total

Source: Euromonitor International from official statistics, trade associations, trade interviews

years

2005 2006 2007 2008 2009 2010

Males
Females
Source: Euromonitor International from official statistics

MARKET DATA

Table 3	Sales of Consun	ner Health by	Category: V	alue 2005-20	10		
SEK million		2005	2006	2007	2008	2009	2010
OTC Sports Nutrition Vitamins and Dir Supplements Weight Manager Herbal/Tradition Products Allergy Care Child-Specific C Health Consumer Healt	ment al onsumer		27		Y		

Source: Euromonitor International from official statistics, trade associations, trade press, company research, store

checks, trade interviews, trade sources

Note: Sum of sectors is greater than the market size because the four allergy care subsectors are included in allergy

care as well as cough, cold and allergy remedies, medicated skin care and eye care.

Table 4 Sales of Consumer Health by Category: % Value Growth 2005-2010 % current value growth 2009/10 2005-10 CAGR 2005/10 TOTAL OTC Sports Nutrition Vitamins and Dietary Supplements Weight Management Herbal/Traditional Products Allergy Care Child-Specific Consumer Health Consumer Health

Source: Euromonitor International from official statistics, trade associations, trade press, company research, store

checks, trade interviews, trade sources

Note: Sum of sectors is greater than the market size because the four allergy care subsectors are included in allergy

care as well as cough, cold and allergy remedies, medicated skin care and eye care.

نمونه گزارشِ تحلیل بازار بهداشت فردی در ایران



Table 5	Consumer Health Company Shares by Value 2006-2010					
% retail value rsp Company	,	2006	2007	2008	2009	2010

Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0 Source: Euromonitor International from official statistics, trade associations, trade press, company research, store

checks, trade interviews, trade sources

Table 6	Consumer	Health Brand Sh	nares by Value 2007-20	0		
% retail valu Brand	e rsp	Company	200	7 2008	2009	2010



Total 100.0 100.0 100.0 100.0

Source: Euromonitor International from official statistics, trade associations, trade press, company research, store checks, trade interviews, trade sources

Table 7 Penetration of Private Label by Category 2005-2010

% retail value rsp

2005 2006 2007 2008 2009 2010

Consumer Health
OTC
Sports Nutrition
Vitamins and Dietary

Supplements
Source: Euromonitor International from official statistics, trade associations, trade press, company research, store checks, trade interviews, trade sources

Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010 % retail value rsp 2005 2006 2007 2008 2009 2010 Store-Based Retailing **Grocery Retailers** Discounters Healthfood shops Hypermarkets Small Grocery Retailers Supermarkets Other Grocery Retailers Non-Grocery Retailers Health and Beauty Retailers Chemists/Pharmacies Parapharmacies/Drugstores Other Healthcare Specialist Retailers



Mass Merchandisers Other Non-Grocery Retailers Non-Store Retailing Vending Homeshopping Internet Retailing Direct Selling 100.0 100.0 100.0 100.0 100.0

Total Source:

Euromonitor International from official statistics, trade associations, trade press, company research, store checks, trade interviews, trade sources

Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010 % retail value rsp OTC SN **VDS** WM HTP AC Store-Based Retailing **Grocery Retailers** Discounters Healthfood shops Hypermarkets **Small Grocery Retailers** Supermarkets Other Grocery Retailers Non-Grocery Retailers Health and Beauty Retailers Chemists/Pharmacies Parapharmacies/Drugstores Other Healthcare Specialist Retailers Mass Merchandisers Other Non-Grocery Retailers Non-Store Retailing Vending Homeshopping Internet Retailing **Direct Selling** 100.0 100.0 100.0 100.0 100.0 100.0 Total **CSCH**

Store-Based Retailing **Grocery Retailers** Discounters Healthfood shops Hypermarkets Small Grocery Retailers Supermarkets Other Grocery Retailers Non-Grocery Retailers Health and Beauty Retailers Chemists/Pharmacies Parapharmacies/Drugstores Other Healthcare **Specialist Retailers** Mass Merchandisers Other Non-Grocery Retailers Non-Store Retailing

Vending



Homeshopping Internet Retailing **Direct Selling** Total 100.0

Source: Euromonitor International from official statistics, trade associations, trade press, company research, store

checks, trade interviews, trade sources

Key: OTC = over the counter; SN = sports nutrition; VDS = vitamins and dietary supplements; WM = weight management; HTP = herbal/traditional products; AC = Allergy Care; CSCH = child-specific consumer health

Table 10 Forecast Sales of Consumer Health by Category: Value 2010-2015 SEK million 2010 2012 2014 2015 2011 2013 OTC Sports Nutrition Vitamins and Dietary Supplements Weight Management Herbal/Traditional **Products** Allergy Care Child-Specific Consumer

Euromonitor International from trade associations, trade press, company research, trade interviews, trade Source:

Note: Sum of sectors is greater than the market size because the four allergy care subsectors are included in allergy

care as well as cough, cold and allergy remedies, medicated skin care and eye care.

Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

% constant value growth

Health Consumer Health

> 2010-15 CAGR 2010/15 TOTAL

Sports Nutrition Vitamins and Dietary Supplements Weight Management Herbal/Traditional Products Allergy Care Child-Specific Consumer Health

Consumer Health

OTC

Euromonitor International from trade associations, trade press, company research, trade interviews, trade Source:

Note: Sum of sectors is greater than the market size because the four allergy care subsectors are included in allergy

care as well as cough, cold and allergy remedies, medicated skin care and eye care.

APPENDIX

OTC Registration and Classification



European regulatory systems











National legislation




Regulation of vitamins and dietary supplements





Regulation of herbal products





Switches

0		haara Caritahaa 2000 2010		
5	ummary 1 OTC Healt	hcare Switches 2008-2010		
	Brand name	Manufacturer	Product type/Ingredient	Switch date
,	Alit	Removed	Removed	Removed
	-	Removed	Removed	Removed
	Lansopazol Mylan 30 mg enterokapsel	Removed	Removed	Removed
	Omeprazol BMM Pharma 20 mg enterotablett	Removed	Removed	Removed
	Bamyl Koffein 500 mgl SOmgtablet	Removed	Removed	Removed
E	Bamyl 500 mg Brustablett	Removed	Removed	Removed
	Bamyl Koffein 500 mgl 50 mg brustablett	Removed	Removed	Removed
	Telfast 120 mg filmdragerad tablet	Removed	Removed	Removed
	Zomig Rapimelt 5 mg munsonderfaflande tablet	Removed	Removed	Removed
•	Toilax 5 mg enterotablett	Removed	· · · · · · · · · · · · · · · · · · ·	Removed برای دریافت اطلاعات بیشتر فن : ۸۸۳٤۹۱۱۲ تماس حاص
			ں حر بہ یہد،	~ ~ (



Cetirizine B	MM Pharma	Removed	Removed	Removed
Sumatriptar Pharma 50		Removed	Removed	Removed
Sumatriptar 50mg	Ratiopharm	Removed	Removed	Removed
Sumatriptar mg	Sandoz 50	Removed	Removed	Removed
Dulcolax 5n	ng	Removed	Removed	Removed
Dulcolax 10	mg	Removed	Removed	Removed
Kestine 10r	ng	Removed	Removed	Removed
Source.	Official statistics,	Lakemedelsverket),	Trade interviews	

DEFINITIONS

This report analyses the market for consumer health in Sweden. For the purposes of the study, the market has been defined as follows:

- ~ Analgesics
- ~ Cough, Cold And Allergy (Hay Fever) Remedies
- ~ Digestive Remedies
- ~ Medicated Skin Care
- ~ NRT Smoking Cessation Aids
- ~ Eye.Care
- ~ Ear Care
- ~ Adult Mouth Care
- ~ Calming and Sleeping Products
- ~ Wound Care
- ~ Emergency Contraception
- ~ OTC Triptans
- ~ Vitamins and Dietary Supplements
- ~ Weight Management
- ~ Sports Nutrition
- ~ Herbal/Traditional Products

Explanations of words and/or terminology used in this report are as follows:

- ~ Leverantorsforeningen for homeopati Swedish trade association for homeopathic therapists and suppliers
- ~ Lakemedelsverket (Swedish) Medical Products Agency.

Sources used during research include the following:

Summary2 ResearchSources

OfficialSources Laksrnedelsverket

L1F

نمونه گزارش تحلیل بازار بهداشت فر<mark>دی در ایران</mark>



Medical Products Agency Trade Associations Apotekens Sevice Association of the European Self-Medication Industry (AESGP) Halsokostcentralen Hatsokostradet Lakemedelsindustriforeningen Svensk Egerward Svesk Handel Trade Press Anarsvarlden Anna Bjore Butikens Varld Dagens Handel Dagens Industri Dagens Media Dagens Medicin Dagens Nyfleter Economic & Legal Framework for Non-Prescription Medicines (AESGP) Fri Kopenskap Hufvudstadsbladet Uikemede'lsvarden Ny Teknik Nyhetsbanken Nyhetsbyran Dlre'kt OTC Bulletin Pharma Online PointLex Resume SVD Ekonomi Svenska Dagbladet Sydsvenska Dagbladet TT Nyhetsbanken TT Spectra Veckans Affarer Waymaker

نشانی؛ تهران، خیابان سهروردی جنوبی، پایین تر از راهنمایی و رانندگی، کوچه اسلامی، پلاک ۴، طبقه ۴، واحد ۱۲ تلفن؛ ۸۸۳۴۹۱۱۲ دورنگار؛ ۸۸۳۴۹۴۳۲

www.passport.ir